Catalent Pharma Solutions LLC

20/10/2026

A promising molecule is just the beginning. Turning scientific potential into clinical progress takes the right development strategy, funding, and partnerships.

Join Catalent for “From Molecule to Milestone: Building and Funding the Path to the Clinic” to explore the critical decisions that can shape a biotech program’s journey from early development toward clinical readiness.

From aligning development priorities with funding strategies to navigating technical challenges and preparing for key milestones, discover how a more integrated approach can help emerging biotechs reduce risk, make informed decisions, and build a stronger foundation for success.

Take the next step toward advancing your molecule.

Register today: https://ow.ly/XzRG50ZZkxc

20/10/2026

What can the right clinical supply partner help make possible for your next study?

At ChinaTrials 18, R&D leaders from China, Asia-Pacific, the U.S. and Europe will come together to share ideas and build partnerships. Catalent will be there too, ready to talk about flexible, comprehensive clinical supply services that can help support your studies.

Come find us at Booth #5 in Shanghai, October 28–30. We’d love to hear what you’re working on.

Book a 1:1 with our experts: https://ow.ly/ML3J50ZZi92

19/10/2026

Your next big idea deserves the right expertise behind it.

Meet Catalent at BIOPLUS INTERPHEX KOREA 2026 October 28-30 Booth #2 COEX Seoul and explore our end-to-end CDMO services across biologics, cell and gene therapies, and small molecules. From drug development and clinical supply to commercial capabilities, our team is here to support your product’s journey from early discovery through market launch.

Let’s talk about your program. Book a meeting with our team: https://ow.ly/CXXa50ZYXun

19/10/2026

Catalent is heading to AAPS PharmSci 360 2026!

Visit us at Booth #1811 to explore how our scientific expertise can help tackle complex challenges across formulation, drug delivery, scale-up, and commercialization.

And don’t miss our experts on stage throughout the event, sharing insights across oral delivery, emerging modalities, inhalation, CMC strategy, and spray drying.

Connect with Catalent and discover new strategies to accelerate your molecule from development to commercial success: https://ow.ly/b8N650ZYY4Z

19/10/2026

Our APAC team is heading to the Gold Coast for Australia’s Biggest Week in Biotech!

Attending the 2026 AusBiotech International Conference? Stop by booth #53 for a chat with the Catalent Clinical Supply Services team about your study’s operational challenges, clinical supply planning, packaging and labelling, and how to get supplies to the right place at the right time. We'll be here 21-23 October!

Want a 1:1? Book a meeting with us: https://ow.ly/2WTS50ZYX0N

19/10/2026

The conversations from GCSG 2026 European Knowledge Forum don’t have to end in Rome.

As clinical supply teams continue navigating increasingly complex global trials, understanding QP requirements across the EU and UK remains critical to maintaining compliance and keeping supply moving.

Continue the conversation with insights from Johannes Hirt, Senior Batch Processing Manager and Qualified Person at Catalent, as he explores key considerations for navigating post-Brexit regulations, mitigating supply chain risk, and engaging QPs early to help prevent avoidable delays.

Download the executive summary to explore how a more strategic approach to QP oversight can help keep clinical trials on track:
https://ow.ly/V6Ug50ZYQS5

16/10/2026

Innovation in drug delivery isn't just about the formulation. It's also about designing manufacturable solutions.

Our scientists recently investigated scalable drum-filling approaches for thin-film freeze-dried monoclonal antibody powders intended for intranasal delivery. The study showed successful low-dose filling while maintaining dose consistency, nasal deposition performance, and antibody stability.

These findings help advance the development of next-generation nasal biologic therapies.

Read the article: https://ow.ly/8zAI50ZYmeS

16/10/2026

The analytical gaps an ADC program accepts in early development tend to return as formulation, stability, and regulatory problems.

This article explains how a phase-appropriate strategy resolves DAR distribution, linker stability, and aggregation risk early enough to guide development from discovery through commercialization.

Download now: https://ow.ly/4Kwb50ZYmtl

15/10/2026

Multispecific and therapies are raising the bar for biologics development, with greater complexity across cell line development, analytics and purification.

In a recent BioSpace article, Catalent’s Laura Daley, Senior Director, Cell Biology & Product Development, shares her insights on how CDMOs are evolving to support these increasingly sophisticated modalities, from precise expression balancing and deeper characterization to flexible downstream strategies and faster data-driven decision-making.

Read the full article to explore how multispecifics are reshaping the CDMO development architecture: https://ow.ly/k3IO50ZXVgi

Manufacturers are being pushed beyond mAb‑era platforms into a new design model built around molecular engineering, complex analytics and amplified upstream and downstream processing.

15/10/2026

Innovation was on full display at the recent 2026 Endpoints 11 Awards as biotechnology's rising stars were recognized for their vision, scientific excellence and commitment to advancing patient outcomes.

Our President & CEO, Alessandro Maselli, joined industry leaders in celebrating this year’s winners and sharing his perspective on the scientific, technological and global trends shaping biotech, as well as the importance of speed, discipline and strong partnerships in bringing therapies to patients.

Read more about the event and access the full 2026 Endpoints 11 Awards recording here: https://ow.ly/JIwm50ZXZGe